Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 73118 [2016-25650]
Download as PDF
73118
Federal Register / Vol. 81, No. 205 / Monday, October 24, 2016 / Notices
technology to minimize the information
collection burden.
Amy McNulty,
Deputy Director, Division of the Executive
Secretariat.
[FR Doc. 2016–25618 Filed 10–21–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood and Tissue Safety and
Availability
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood and
Tissue Safety and Availability
(ACBTSA) will hold a meeting. The
meeting will be open to the public.
DATES: The meeting will take place
Monday November 28, 2016, from 9:30
a.m.–4:00 p.m. and Tuesday November
29, 2016, from 8:30 a.m.–4:00 p.m.
ADDRESSES: Veterans’ Health
Administration National Conference
Center, 2011 Crystal Drive, 1st floor
Conference Center, Crystal City, VA
22202.
FOR FURTHER INFORMATION CONTACT: Mr.
James Berger, Designated Federal Officer
for the ACBTSA, Senior Advisor for
Blood and Tissue Policy, Office of the
Assistant Secretary for Health,
Department of Health and Human
Services, Mary E. Switzer Building, 330
C Street SW., Suite L100, Washington,
DC 20024. Phone: (202)-795–7697; Fax:
(202)-691–2102; Email: ACBTSA@
hhs.gov.
SUPPLEMENTARY INFORMATION: The
ACBTSA provides advice to the
Secretary through the Assistant
Secretary for Health. The Committee
advises on a range of policy issues to
include: (1) Identification of public
health issues through surveillance of
blood and tissue safety issues with
national biovigilance data tools; (2)
identification of public health issues
that affect availability of blood, blood
products, and tissues; (3) broad public
health, ethical, and legal issues related
to the safety of blood, blood products,
and tissues; (4) the impact of various
economic factors (e.g., product cost and
supply) on safety and availability of
blood, blood products, and tissues; (5)
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:42 Oct 21, 2016
Jkt 241001
risk communications related to blood
transfusion and tissue transplantation;
and (6) identification of infectious
disease transmission issues for blood,
organs, blood stem cells and tissues.
The Committee has met regularly since
its establishment in 1997.
In December 2013, the Committee
made recommendations regarding the
blood system. At that time, the
Committee expressed concern about the
ongoing reductions in blood use, the
number of large scale consolidations
occurring, the cost recovery issues for
blood centers, and the potential effects
on safety and innovation due to
instability. In November 2015, the
Committee made recommendations
again, reaffirming the December 2013
recommendations, highlighting the
worsening conditions, and suggesting
potential initiatives to address the
issues in the blood system. Past
recommendations made by the ACBTSA
may be viewed at https://www.hhs.gov/
ohaidp/initiatives/blood-tissue-safety/
advisory-committee/.
The Committee will meet on
November 28–29, 2016 to hear the
findings from the HHS sponsored RAND
study, ‘‘Toward a Sustainable Blood
Supply in the United States: An
Analysis of the Current System and
Alternatives for the Future.’’ The
ACBTSA Subcommittee on Blood
System Sustainability will present their
response to the study, and the full
Committee will discuss and develop
appropriate recommendations for HHS
consideration. Additional topics that are
pertinent to the mission of the
Committee may be added to the agenda.
The public will have an opportunity
to present their views to the Committee
during public comment sessions
scheduled for both days of the meeting.
Comments will be limited to five
minutes per speaker and must be
pertinent to the discussion. Preregistration is required for participation
in the public comment session. Any
member of the public who would like to
participate in this session is required to
submit their name, email, and comment
summary prior to close of business on
November 17, 2016. If it is not possible
to provide 30 copies of the material to
be distributed at the meeting, then
individuals are requested to provide a
minimum of one (1) copy of the
document(s) to be distributed prior to
the close of business on November 17,
2016. It is also requested that any
member of the public who wishes to
provide comments to the Committee
utilizing electronic data projection
submit the necessary material to the
Designated Federal Officer prior to the
close of business on November 17, 2016.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Dated: October 18, 2016.
James J. Berger,
Senior Advisor for Blood and Tissue Policy.
[FR Doc. 2016–25650 Filed 10–21–16; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Health Services Organization and
Delivery.
Date: November 3, 2016.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Peter J Kozel, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
Bethesda, MD 20892, 301–435–1116, kozelp@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 14–
260: Health Promotion and Disease
Prevention among Native American
Populations.
Date: November 4, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Martha L Hare, RN, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3154,
MSC 7770, Bethesda, MD 20892, (301) 451–
8504, harem@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
E:\FR\FM\24OCN1.SGM
24OCN1
Agencies
[Federal Register Volume 81, Number 205 (Monday, October 24, 2016)]
[Notices]
[Page 73118]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-25650]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Advisory Committee on Blood and Tissue Safety and Availability
(ACBTSA) will hold a meeting. The meeting will be open to the public.
DATES: The meeting will take place Monday November 28, 2016, from 9:30
a.m.-4:00 p.m. and Tuesday November 29, 2016, from 8:30 a.m.-4:00 p.m.
ADDRESSES: Veterans' Health Administration National Conference Center,
2011 Crystal Drive, 1st floor Conference Center, Crystal City, VA
22202.
FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal
Officer for the ACBTSA, Senior Advisor for Blood and Tissue Policy,
Office of the Assistant Secretary for Health, Department of Health and
Human Services, Mary E. Switzer Building, 330 C Street SW., Suite L100,
Washington, DC 20024. Phone: (202)-795-7697; Fax: (202)-691-2102;
Email: ACBTSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The ACBTSA provides advice to the Secretary
through the Assistant Secretary for Health. The Committee advises on a
range of policy issues to include: (1) Identification of public health
issues through surveillance of blood and tissue safety issues with
national biovigilance data tools; (2) identification of public health
issues that affect availability of blood, blood products, and tissues;
(3) broad public health, ethical, and legal issues related to the
safety of blood, blood products, and tissues; (4) the impact of various
economic factors (e.g., product cost and supply) on safety and
availability of blood, blood products, and tissues; (5) risk
communications related to blood transfusion and tissue transplantation;
and (6) identification of infectious disease transmission issues for
blood, organs, blood stem cells and tissues. The Committee has met
regularly since its establishment in 1997.
In December 2013, the Committee made recommendations regarding the
blood system. At that time, the Committee expressed concern about the
ongoing reductions in blood use, the number of large scale
consolidations occurring, the cost recovery issues for blood centers,
and the potential effects on safety and innovation due to instability.
In November 2015, the Committee made recommendations again, reaffirming
the December 2013 recommendations, highlighting the worsening
conditions, and suggesting potential initiatives to address the issues
in the blood system. Past recommendations made by the ACBTSA may be
viewed at https://www.hhs.gov/ohaidp/initiatives/blood-tissue-safety/advisory-committee/.
The Committee will meet on November 28-29, 2016 to hear the
findings from the HHS sponsored RAND study, ``Toward a Sustainable
Blood Supply in the United States: An Analysis of the Current System
and Alternatives for the Future.'' The ACBTSA Subcommittee on Blood
System Sustainability will present their response to the study, and the
full Committee will discuss and develop appropriate recommendations for
HHS consideration. Additional topics that are pertinent to the mission
of the Committee may be added to the agenda.
The public will have an opportunity to present their views to the
Committee during public comment sessions scheduled for both days of the
meeting. Comments will be limited to five minutes per speaker and must
be pertinent to the discussion. Pre-registration is required for
participation in the public comment session. Any member of the public
who would like to participate in this session is required to submit
their name, email, and comment summary prior to close of business on
November 17, 2016. If it is not possible to provide 30 copies of the
material to be distributed at the meeting, then individuals are
requested to provide a minimum of one (1) copy of the document(s) to be
distributed prior to the close of business on November 17, 2016. It is
also requested that any member of the public who wishes to provide
comments to the Committee utilizing electronic data projection submit
the necessary material to the Designated Federal Officer prior to the
close of business on November 17, 2016.
Dated: October 18, 2016.
James J. Berger,
Senior Advisor for Blood and Tissue Policy.
[FR Doc. 2016-25650 Filed 10-21-16; 8:45 am]
BILLING CODE 4150-41-P